Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Alza Considering Viadur Marketing Partner For Late 2000 Launch

  • News

Executive Summary

Alza is considering whether to find a marketing partner for Viadur in anticipation of a late 2000/early 2001 launch for the long-acting implant for palliative treatment of advanced prostate cancer.

You may also be interested in...



Pharmacia Trelstar Depot Approval Gives Company Prostate Cancer Therapy

Pharmacia will add a prostate cancer therapy to its oncology products portfolio following approval of Trelstar Depot June 15.

Pharmacia Trelstar Depot Approval Gives Company Prostate Cancer Therapy

Pharmacia will add a prostate cancer therapy to its oncology products portfolio following approval of Trelstar Depot June 15.

Bayer To Market Alza Viadur In U.S.; Weighs International Agreement

Bayer is considering an international marketing arrangement for Alza's Viadur following an agreement to market the long-acting leuprolide acetate implant for prostate cancer in the U.S.

Table

View full table

Tags:
Latest Headlines

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

Changes To EU Pharma Reform: More Questions Than Answers?

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

See All
UsernamePublicRestriction

Register

PS035716

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By